Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Debt (2016 - 2023)

Historic Total Debt for Cartesian Therapeutics (RNAC) over the last 9 years, with Q4 2023 value amounting to $28.3 million.

  • Cartesian Therapeutics' Total Debt rose 778.69% to $28.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $28.3 million, marking a year-over-year increase of 778.69%. This contributed to the annual value of $28.3 million for FY2023, which is 778.69% up from last year.
  • As of Q4 2023, Cartesian Therapeutics' Total Debt stood at $28.3 million, which was up 778.69% from $24.0 million recorded in Q2 2023.
  • Cartesian Therapeutics' 5-year Total Debt high stood at $28.3 million for Q4 2023, and its period low was $14.8 million during Q2 2020.
  • Over the past 5 years, Cartesian Therapeutics' median Total Debt value was $25.0 million (recorded in 2021), while the average stood at $23.6 million.
  • Its Total Debt has fluctuated over the past 5 years, first tumbled by 3116.3% in 2020, then skyrocketed by 7003.98% in 2021.
  • Cartesian Therapeutics' Total Debt (Quarter) stood at $18.9 million in 2019, then soared by 31.15% to $24.8 million in 2020, then rose by 3.39% to $25.6 million in 2021, then rose by 2.45% to $26.3 million in 2022, then rose by 7.79% to $28.3 million in 2023.
  • Its last three reported values are $28.3 million in Q4 2023, $24.0 million for Q2 2023, and $26.4 million during Q1 2023.